Veracyte

Update in progress

VCYT (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

Veracyte, Inc. is a diagnostics company that develops genomic tests to inform cancer care. Its offerings include Afirma for thyroid nodules, Decipher Prostate and Decipher Bladder for cancer diagnosis, Prosigna for breast cancer, Percepta for lung cancer, and related nCounter analysis system services. Formerly Calderome, Inc., it was renamed Veracyte in 2008, and was incorporated in 2006. Headquartered in South San Francisco, California.

Company score

Sentiment: 0.39; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.34; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.12; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.25; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive